GenomiCare Biotechnology joins the Roche Accelerator
Shanghai,June 8th, 2022 - GenomiCare Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as GenomiCare Biotechnology) announces acceptance by the Roche Accelerator. With the support from Roche Accelerator, GenomiCare Biotechnology will further devote...
Highlights from ISPOR (Real World China)
GenomiCare’s sponsored ISPOR Webinar featured a cast of experts from Novartis, Roche, and AstraZeneca in a engaging discussion about Real World Evidence in China. Key takeaways included: On the data, itself: Representativeness and Quality of data is paramount Overall...
ISPOR Webinar- China RWE/RWD
On June 29th, GenomiCare Biotechnology hosted an ISPOR webinar about the opportunities/challenges of RWE/RWD collection from China.
GenomiCare Is on List of 2020 Deloitte China Technology Fast 50 & China Rising Star
The 2020 China Technology Fast 50 & China Rising Star lists were officially published by the Beijing office of Deloitte on December 9 and reported by dozens of news outlets. GenomiCare is on list of the 2020 China Rising Star thanks to its “two-wheel-drive” business model, powerful translational cancer research, and flexible data solutions for clinical oncology drug development.
GenomiCare Wins Two Awards at 2020 International Sci-Tech Innovation Festival
GenomiCare is proud to announce that it has won the 2020 Leading Sci-Tech Innovation Company Award for its innovations in the R&D of cancer precision medicine, and that Dr. Xu Qiang, the company’s founder and CEO, has been named a 2020 Sci-Tech Innovation Leader.
GenomiCare Partners with AWS on HIPAA Eligible Services for Higher Data Security
GenomiCare, Inc. has recently reached a cooperation agreement with AWS on HIPAA compliance. This enables GenomiCare to store, process and utilize masked clinical data in a safer environment and therefore ensures the security and availability of personal health information (PHI) for our clients all over the world.
GenomiCare unveiled the results of PD-L1 immunohistochemistry images in outcome prediction at ASCO 2020
Recently, the summary of the results of GenomiCare PD-L1 immunohistochemistry (IHC) images in outcome prediction was included in the ASCO 2020 (56th Annual Meeting of the American Society of Clinical Oncology), entitled “Application of Automated Segmentation and Classification of PD-L1 Immunohistochemistry Images in Cancer Treatment Prediction”.